The impact of biological and targeted synthetic disease-modifying antirheumatic drugs on patient costs: a cross-sectional study.
OBJECTIVES Financial toxicity, defined as the detrimental impact of treatment-related costs on patients' lifestyles, has gained increasing recognition and is now managed similarly to treatment-related physical toxicities. We aimed to investigate the association between the use of biologic or targeted synthetic disease-...